5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression

Luisella Bocchio-Chiavetto, Carlo Miniussi, Roberta Zanardini, Anna Gazzoli, Stefano Bignotti, Claudia Specchia, Massimo Gennarelli

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is a painless and safe brain stimulation technique that has been found to be effective in treating depression symptoms. The potential usefulness of rTMS, in particular to treat drug resistant patients, might be increased by identifying genetic predictors of efficacy. According to this rationale, we investigated the role of two functional polymorphisms in the genes coding for the serotonin transporter (5-HTTLPR) and the brain-derived neurotrophic factor (BDNF Val66Met), and rTMS response in a group of 36 drug resistant patients affected by mood disorders. rTMS treatment significantly improved depression symptomatology (p <0.0001) and the response was significantly greater in 5-HTTLPR LL homozygotes compared to S allele carriers (p = 0.007) and in BDNF Val/Val homozygotes compared to Met allele carriers (p = 0.024). These findings provide evidences about the involvement of both polymorphisms in rTMS antidepressant response. Further investigations in larger samples are needed to clarify the usefulness of 5-HTTLPR and BDNF Val66Met genotyping in the optimization of non-pharmacological treatments in mood disorders.

Original languageEnglish
Pages (from-to)130-134
Number of pages5
JournalNeuroscience Letters
Volume437
Issue number2
DOIs
Publication statusPublished - May 30 2008

Fingerprint

Transcranial Magnetic Stimulation
Brain-Derived Neurotrophic Factor
Depression
Pharmaceutical Preparations
Homozygote
Mood Disorders
Alleles
Therapeutics
Serotonin Plasma Membrane Transport Proteins
Antidepressive Agents
Brain
Genes

Keywords

  • 5-HTTLPR
  • Antidepressant
  • BDNF
  • Depression
  • rTMS
  • Val66Met

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. / Bocchio-Chiavetto, Luisella; Miniussi, Carlo; Zanardini, Roberta; Gazzoli, Anna; Bignotti, Stefano; Specchia, Claudia; Gennarelli, Massimo.

In: Neuroscience Letters, Vol. 437, No. 2, 30.05.2008, p. 130-134.

Research output: Contribution to journalArticle

@article{ed61431501c8431bba9df1fa65d1a68d,
title = "5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression",
abstract = "Repetitive transcranial magnetic stimulation (rTMS) is a painless and safe brain stimulation technique that has been found to be effective in treating depression symptoms. The potential usefulness of rTMS, in particular to treat drug resistant patients, might be increased by identifying genetic predictors of efficacy. According to this rationale, we investigated the role of two functional polymorphisms in the genes coding for the serotonin transporter (5-HTTLPR) and the brain-derived neurotrophic factor (BDNF Val66Met), and rTMS response in a group of 36 drug resistant patients affected by mood disorders. rTMS treatment significantly improved depression symptomatology (p <0.0001) and the response was significantly greater in 5-HTTLPR LL homozygotes compared to S allele carriers (p = 0.007) and in BDNF Val/Val homozygotes compared to Met allele carriers (p = 0.024). These findings provide evidences about the involvement of both polymorphisms in rTMS antidepressant response. Further investigations in larger samples are needed to clarify the usefulness of 5-HTTLPR and BDNF Val66Met genotyping in the optimization of non-pharmacological treatments in mood disorders.",
keywords = "5-HTTLPR, Antidepressant, BDNF, Depression, rTMS, Val66Met",
author = "Luisella Bocchio-Chiavetto and Carlo Miniussi and Roberta Zanardini and Anna Gazzoli and Stefano Bignotti and Claudia Specchia and Massimo Gennarelli",
year = "2008",
month = "5",
day = "30",
doi = "10.1016/j.neulet.2008.04.005",
language = "English",
volume = "437",
pages = "130--134",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression

AU - Bocchio-Chiavetto, Luisella

AU - Miniussi, Carlo

AU - Zanardini, Roberta

AU - Gazzoli, Anna

AU - Bignotti, Stefano

AU - Specchia, Claudia

AU - Gennarelli, Massimo

PY - 2008/5/30

Y1 - 2008/5/30

N2 - Repetitive transcranial magnetic stimulation (rTMS) is a painless and safe brain stimulation technique that has been found to be effective in treating depression symptoms. The potential usefulness of rTMS, in particular to treat drug resistant patients, might be increased by identifying genetic predictors of efficacy. According to this rationale, we investigated the role of two functional polymorphisms in the genes coding for the serotonin transporter (5-HTTLPR) and the brain-derived neurotrophic factor (BDNF Val66Met), and rTMS response in a group of 36 drug resistant patients affected by mood disorders. rTMS treatment significantly improved depression symptomatology (p <0.0001) and the response was significantly greater in 5-HTTLPR LL homozygotes compared to S allele carriers (p = 0.007) and in BDNF Val/Val homozygotes compared to Met allele carriers (p = 0.024). These findings provide evidences about the involvement of both polymorphisms in rTMS antidepressant response. Further investigations in larger samples are needed to clarify the usefulness of 5-HTTLPR and BDNF Val66Met genotyping in the optimization of non-pharmacological treatments in mood disorders.

AB - Repetitive transcranial magnetic stimulation (rTMS) is a painless and safe brain stimulation technique that has been found to be effective in treating depression symptoms. The potential usefulness of rTMS, in particular to treat drug resistant patients, might be increased by identifying genetic predictors of efficacy. According to this rationale, we investigated the role of two functional polymorphisms in the genes coding for the serotonin transporter (5-HTTLPR) and the brain-derived neurotrophic factor (BDNF Val66Met), and rTMS response in a group of 36 drug resistant patients affected by mood disorders. rTMS treatment significantly improved depression symptomatology (p <0.0001) and the response was significantly greater in 5-HTTLPR LL homozygotes compared to S allele carriers (p = 0.007) and in BDNF Val/Val homozygotes compared to Met allele carriers (p = 0.024). These findings provide evidences about the involvement of both polymorphisms in rTMS antidepressant response. Further investigations in larger samples are needed to clarify the usefulness of 5-HTTLPR and BDNF Val66Met genotyping in the optimization of non-pharmacological treatments in mood disorders.

KW - 5-HTTLPR

KW - Antidepressant

KW - BDNF

KW - Depression

KW - rTMS

KW - Val66Met

UR - http://www.scopus.com/inward/record.url?scp=43049161158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43049161158&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2008.04.005

DO - 10.1016/j.neulet.2008.04.005

M3 - Article

VL - 437

SP - 130

EP - 134

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -